Suppr超能文献

理解代谢型谷氨酸受体 5 负变构调节剂在一系列临床前和临床研究中的暴露-受体占有率关系。

Understanding Exposure-Receptor Occupancy Relationships for Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators across a Range of Preclinical and Clinical Studies.

机构信息

Sosei Heptares, Cambridge, CB21 6DG, United Kingdom.

Sosei Heptares, Cambridge, CB21 6DG, United Kingdom

出版信息

J Pharmacol Exp Ther. 2021 Apr;377(1):157-168. doi: 10.1124/jpet.120.000371. Epub 2021 Feb 4.

Abstract

The metabotropic glutamate receptor 5 (mGlu) is a recognized central nervous system therapeutic target for which several negative allosteric modulator (NAM) drug candidates have or are continuing to be investigated for various disease indications in clinical development. Direct measurement of target receptor occupancy (RO) is extremely useful to help design and interpret efficacy and safety in nonclinical and clinical studies. In the mGlu field, this has been successfully achieved by monitoring displacement of radiolabeled ligands, specifically binding to the mGlu receptor, in the presence of an mGlu NAM using in vivo and ex vivo binding in rodents and positron emission tomography imaging in cynomolgus monkeys and humans. The aim of this study was to measure the RO of the mGlu NAM HTL0014242 in rodents and cynomolgus monkeys and to compare its plasma and brain exposure-RO relationships with those of clinically tested mGlu NAMs dipraglurant, mavoglurant, and basimglurant. Potential sources of variability that may contribute to these relationships were explored. Distinct plasma exposure-response relationships were found for each mGlu NAM, with >100-fold difference in plasma exposure for a given level of RO. However, a unified exposure-response relationship was observed when both unbound brain concentration and mGlu affinity were considered. This relationship showed <10-fold overall difference, was fitted with a Hill slope that was not significantly different from 1, and appeared consistent with a simple E model. This is the first time this type of comparison has been conducted, demonstrating a unified brain exposure-RO relationship across several species and mGlu NAMs with diverse properties. SIGNIFICANCE STATEMENT: Despite the long history of mGlu as a therapeutic target and progression of multiple compounds to the clinic, no formal comparison of exposure-receptor occupancy relationships has been conducted. The data from this study indicate for the first time that a consistent, unified relationship can be observed between exposure and mGlu receptor occupancy when unbound brain concentration and receptor affinity are taken into account across a range of species for a diverse set of mGlu negative allosteric modulators, including a new drug candidate, HTL0014242.

摘要

代谢型谷氨酸受体 5(mGluR5)是中枢神经系统的一个公认治疗靶点,已有多种负变构调节剂(NAM)候选药物针对各种疾病适应证在临床开发中进行研究。直接测量靶受体占有率(RO)对于帮助设计和解释非临床和临床研究中的疗效和安全性非常有用。在 mGlu 领域,这已通过监测放射性标记配体的置换来成功实现,具体方法是在存在 mGlu NAM 的情况下监测啮齿动物体内和体外以及食蟹猴和人类的正电子发射断层扫描成像中 mGlu 受体的特异性结合。本研究的目的是测量 mGlu NAM HTL0014242 在啮齿动物和食蟹猴中的 RO,并比较其血浆和脑暴露-RO 与已在临床上测试的 mGlu NAMs(二苯戊胺、马维谷氨酸酯和巴西米谷氨酸酯)的关系。探索了可能导致这些关系的潜在变异性来源。发现每种 mGlu NAM 都有独特的血浆暴露-反应关系,对于给定的 RO 水平,血浆暴露差异超过 100 倍。然而,当同时考虑未结合的脑浓度和 mGlu 亲和力时,观察到统一的暴露-反应关系。这种关系的整体差异小于 10 倍,拟合的希尔斜率与 1 没有显著差异,并且似乎与简单的 E 模型一致。这是首次进行此类比较,证明了几种物种和具有不同特性的 mGlu NAMs 之间存在统一的脑暴露-RO 关系。意义声明:尽管 mGlu 作为治疗靶点已有很长的历史,并且有多种化合物进入临床,但尚未对暴露-受体占有率关系进行正式比较。本研究的数据首次表明,当考虑到一系列物种的未结合脑浓度和受体亲和力时,可以观察到一种一致的、统一的关系,这种关系可以在一组不同的 mGlu 负变构调节剂(包括一种新的候选药物 HTL0014242)之间建立,包括一种新的候选药物 HTL0014242。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验